-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $38

Benzinga·03/18/2026 12:37:39
Listen to the news
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $36 to $38.